Head-To-Head Survey: Genetic Technologies (NASDAQ:GENE) vs. DBV Technologies (NASDAQ:DBVT)

Genetic Technologies (NASDAQ:GENE) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Genetic Technologies and DBV Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genetic Technologies	0	0	0	0	N/A
DBV Technologies	1	0	2	0	2.33

DBV Technologies has a consensus price target of $6.67, indicating a potential upside of 703.21%. Given DBV Technologies’ higher possible upside, analysts clearly believe DBV Technologies is more favorable than Genetic Technologies.

Insider & Institutional Ownership

0.6% of Genetic Technologies shares are owned by institutional investors. Comparatively, 71.7% of DBV Technologies shares are owned by institutional investors. 6.5% of Genetic Technologies shares are owned by company insiders. Comparatively, 1.9% of DBV Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Genetic Technologies has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

Valuation and Earnings

This table compares Genetic Technologies and DBV Technologies’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genetic Technologies	$5.85 million	0.68	-$7.91 million	N/A	N/A
DBV Technologies	$15.73 million	5.09	-$72.73 million	($0.84)	-0.99

Genetic Technologies has higher earnings, but lower revenue than DBV Technologies.

Profitability

This table compares Genetic Technologies and DBV Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genetic Technologies	N/A	N/A	N/A
DBV Technologies	-530.89%	-56.76%	-43.18%

Summary

Genetic Technologies beats DBV Technologies on 6 of the 11 factors compared between the two stocks.

About Genetic Technologies

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

About DBV Technologies

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.